Isofol Medical AB (publ)
SSE:ISOFOL.ST
0.616 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.721 | 12.797 | 22.407 | 37.119 | 0 | 0 | 0.227 | 0.508 | 0.187 | 0 |
| Cost of Revenue
| 42.597 | 178.504 | 226.029 | 199.535 | 1.554 | 0.157 | 0.157 | 0.132 | 0.11 | 0 |
| Gross Profit
| -41.876 | -165.707 | -203.622 | -162.416 | -1.554 | -0.157 | 0.07 | 0.376 | 0.077 | 0 |
| Gross Profit Ratio
| -58.08 | -12.949 | -9.087 | -4.376 | 0 | 0 | 0.308 | 0.74 | 0.41 | 0 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 196.712 | 199.535 | 137.817 | 72.116 | 61.21 | 57.084 | 34.898 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 7.424 | 34.748 | 196.712 | 199.535 | 137.817 | 72.116 | 61.21 | 57.084 | 34.898 | 12.478 |
| Other Expenses
| 42.405 | 180.257 | 30.16 | 24.079 | 29.987 | 17.733 | 11.377 | 6.933 | 5.79 | 0 |
| Operating Expenses
| 42.405 | 180.257 | 226.872 | 223.614 | 167.804 | 89.849 | 72.587 | 64.017 | 40.688 | 10.53 |
| Operating Income
| -41.876 | -167.46 | -204.465 | -186.494 | -167.804 | -89.849 | -72.587 | -64.017 | -40.688 | -10.53 |
| Operating Income Ratio
| -58.08 | -13.086 | -9.125 | -5.024 | 0 | 0 | -319.767 | -126.018 | -217.583 | 0 |
| Total Other Income Expenses Net
| 4.805 | 7.705 | 4.214 | -2.497 | 6.221 | 6.724 | 0.552 | -0.001 | -0.001 | -0.071 |
| Income Before Tax
| -37.071 | -159.755 | -200.251 | -188.991 | -161.583 | -83.125 | -72.035 | -64.018 | -40.689 | -10.601 |
| Income Before Tax Ratio
| -51.416 | -12.484 | -8.937 | -5.091 | 0 | 0 | -317.335 | -126.02 | -217.588 | 0 |
| Income Tax Expense
| -0.131 | -3.812 | -3.367 | 0.001 | -4.352 | 7.362 | 0.558 | 0.001 | 0 | 0 |
| Net Income
| -37.071 | -155.943 | -196.884 | -188.992 | -157.231 | -83.125 | -72.035 | -64.018 | -40.689 | -10.601 |
| Net Income Ratio
| -51.416 | -12.186 | -8.787 | -5.092 | 0 | 0 | -317.335 | -126.02 | -217.588 | 0 |
| EPS
| -0.23 | -0.97 | -1.57 | -2.43 | -2.79 | -1.48 | -1.48 | -2.26 | -1.38 | -1.53 |
| EPS Diluted
| -0.23 | -0.97 | -1.57 | -2.43 | -2.79 | -1.48 | -1.47 | -2.26 | -1.38 | -1.53 |
| EBITDA
| -41.839 | -161.881 | -202.022 | -185.054 | -164.381 | -86.768 | -71.872 | -63.884 | -40.578 | -10.423 |
| EBITDA Ratio
| -58.029 | -12.65 | -9.016 | -4.985 | 0 | 0 | -316.617 | -125.756 | -216.995 | 0 |